Trial · NCT00927485
Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
NCT00927485, Not applicable, Completed, University of Puerto Rico; results first posted 2020-12-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP). Trials, record NCT00927485. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00927485
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
- NCT number
- NCT00927485
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 44 participants, actual
- Lead sponsor
- University of Puerto Rico
- Conditions
- Familial Adenomatous Polyposis
- Interventions
- Calcumin (Curcumin), Risk Factor Questionnaire, Blood samples, Biopsies (Sigmoidoscopy), Biopsies (Upper endoscopy)
- First posted
- 2009-06-25
- Last updated
- 2020-12-16
- Results first posted
- 2020-12-16
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Polyps | 5 years | To determine in a randomized, double-blinded, placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp number in patients with FAP. |
| Primary | Size of Polyps | 5 years | To determine in a randomized, double-blinded, placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp size in patients with FAP. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Polyps | 5 years | Number of Polyps | MEAN | |
| PRIMARY | Size of Polyps | 5 years | mm | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Polyps | Curcumin | 18.6 | 95% Confidence Interval 12.1 to 33.1 | Number of Polyps | |
| Number of Polyps | Placebo | 22.6 | 95% Confidence Interval 9.93 to 27.8 | Number of Polyps | |
| Size of Polyps | Curcumin | 2.3 | 95% Confidence Interval 1.8 to 2.8 | mm | |
| Size of Polyps | Placebo | 2.1 | 95% Confidence Interval 1.5 to 2.7 | mm |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Curcumin | 21 | |
| Overall Study | STARTED | Placebo | 23 | |
| Overall Study | COMPLETED | Curcumin | 15 | |
| Overall Study | COMPLETED | Placebo | 19 | |
| Overall Study | NOT COMPLETED | Curcumin | 6 | |
| Overall Study | NOT COMPLETED | Placebo | 4 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain | Gastrointestinal disorders | Curcumin | 3 | 21 | 3 |
| other | Abdominal Pain | Gastrointestinal disorders | Placebo | 3 | 23 | 3 |
| other | Diarrhea | Gastrointestinal disorders | Curcumin | 2 | 21 | 2 |
| other | Diarrhea | Gastrointestinal disorders | Placebo | 2 | 23 | 2 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Curcumin | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Curcumin | 5 | 21 |
| Total, other adverse events | Placebo | 5 | 23 |
| Total, serious adverse events | Curcumin | 0 | 21 |
| Total, serious adverse events | Placebo | 0 | 23 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29802852 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Curcumin vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00927485
GET https://conductscience.org/api/trials/v1/NCT00927485/registered